跳至主要内容
临床试验/DRKS00027245
DRKS00027245招募中不适用

on-interventional clinical performance study on the use of HPV16 L1 antibody assays Prevo-Check and PT Monitor in the aid of the diagnosis of HPV16-induced tumors in patients with oropharyngeal cancer - PRECISE I

Abviris Deutschland GmbH0 个研究点目标入组 360 人开始时间: 2022年1月20日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
入组人数
360

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
18 Years 至 one(—)
性别
All

入选标准

  • 1. =18 years
  • 2. willingness and ability to provide informed consent.
  • 3. signed informed consent form
  • 4. Suspected diagnosis: oropharyngeal carcinoma (ICD-10 C01 (base of tongue) or C09 (tonsil)).
  • 5. willingness to participate in the study PRECISE ENT II

排除标准

  • 1. a surgical or medical circumstance that would place the patient at increased risk from the study. The investigator will make the decision based on the patient's medical history and/or clinical picture or laboratory results.
  • 2. patients who have been vaccinated against HPV or will be vaccinated in the course of the study
  • 3. therapy for oropharyngeal carcinoma started before inclusion in the study
  • 4. participation in any other clinical trial other than observational studies
  • 5. known other current or previously diagnosed HPV-related carcinomas, e.g., cervical or anal carcinoma (as verbally informed by patient).

研究者

相似试验